The use of immune checkpoint inhibitors has led to improved outcomes for patients in multiple disease sites; however, for some, acquired resistance limits drug efficacy. Our research examines novel mechanisms of resistance that involve intracellular PD-L1 signaling, interferon signaling, secretory pathways that can suppress anti-tumor immunity and also affect efficacy of secondary treatments given after immunotherapy failure.

John Ebos, PhD